Itraconazole
- PDF / 151,352 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 126 Views
1 S
Symmetrical drug-related intertriginous and flexural exanthema: case report A 45-year-old man developed symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) during treatment with itraconazole for tinea corporis. The man presented to a clinic with an intensely pruritic rash over his buttocks, groin and bilateral axilla without any systemic symptoms for the previous 1 week. He had received oral itraconazole 100mg two times daily for tinea corporis, 10 days prior to presentation. About 3–4 days following the initiation of itraconazole, he developed severe itching in his buttock, groin and axillary area, followed by an erythematous and scaly eruption in those regions. He had no history of intake of new food or any other drug except itraconazole. He denied application of any topical irritants. Examination showed well-demarcated, large, scaly, V-shaped erythematous plaques in a bilaterally symmetrical manner in the inguinal and axillary areas, extending upto the scrotum. Similar lesions were also noted on the buttocks and perianal area. No mucosal lesions were observed. Routine urine, blood and biochemical investigations were normal, except for eosinophilia (16%). Skin scraping for KOH mount was negative. Based on the mode of onset, laboratory data, clinical manifestations and temporal association with the drug, a diagnosis of SDRIFE was made. The man’s treatment with itraconazole was discontinued, and he received unspecified oral and topical steroids, along with unspecified antihistaminics. The lesions resolved completely by 1 week, without any recurrence following discontinuation of the steroids. Kalita BJ, et al. Itraconazole-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): a rare occurrence. International Journal of Dermatology : 803499320 2020. Available from: URL: http://doi.org/10.1111/ijd.15049
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
